Where is AVROBIO located?

AVROBIO is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of AVROBIO?

Chris Mason and Geoff MacKay s of AVROBIO.

How many employees does AVROBIO have?

As of Dec 31, 2022, the latest employee count at AVROBIO is 114.

Is AVROBIO a funded company?

AVROBIO is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does AVROBIO rank among its competitors?

AVROBIO ranks 107th amongst 128 active competitors, of which 44 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Mirum Pharmaceuticals, which secured $68.5M in Jan, 2026.

Who are the top competitors of AVROBIO?

AVROBIO's top competitors include BioMarin Pharmaceutical, Ultragenyx and Pharvaris. Among them, Mirum Pharmaceuticals secured the most recent funding round in January, 2026.

AVROBIO - 2026 Company Profile, Team & Competitors

Company Details

AVROBIO is a provider of lentiviral gene therapy for the treatment of Fabry diseases. It has developed VR-RD-01 is an investigational, ex vivo lentiviral gene therapy developed as a single-dose therapy with the potential to provide life-long therapeutic benefit for patients with Fabry disease. It is a lentiviral vector system that is designed to be an efficient gene transfer system with the goal of permanent integration of functional copies of the AGA transgene into an individual’s own stem cells.

Website: avrobiofabrytrial.com
Email ID: *****@avrobio.com
Phone Number: +1 **********
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2019

Location

Cambridge, United States

Stage

Deadpooled

Ranked

107^th among 128 active competitors

Employee Count

114 as on Dec 31, 2022

Similar Companies

Azafaros & 27 more

View AVROBIO's full profile

AVROBIO is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AVROBIO, INC CIN: 810710585 , United States, Active	Dec 31, 2015	-	70 (As on Dec 31, 2022)	-

AVROBIO has not raised any funding rounds yet.

The founders of AVROBIO are Chris Mason and Geoff MacKay.

Here are the details of AVROBIO's key team members:

Chris Mason: Co-Founder & CEO of AVROBIO and founder of 1 other company. They serve on the board of 1 company.
Geoff MacKay: Founder & CEO of AVROBIO.

View details of AVROBIO's Founder profiles and Board Members

AVROBIO's employee count trend

AVROBIO has 114 employees as of Dec 22. The total employee count is the same as what it was in Dec 21. Here is AVROBIO's employee count trend over the years:

Uncover AVROBIO's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AVROBIO include BioMarin Pharmaceutical, Ultragenyx and Pharvaris. Here is the list of Top 10 competitors of AVROBIO, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	MPM Capital, Temasek & 7 others	72/100
2nd	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Healthcap & 10 others	69/100
3rd	Pharvaris 2015, Leiden (Netherlands), Public	Orally deliverable bradykinin B2 antagonists for hereditary angioedema	$164M	Foresite Capital, Life Sciences Partners & 9 others	67/100
4th	ProQR Therapeutics 2012, Leiden (Netherlands), Public	Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders	$58M	Sofinnova Partners, Gilde Healthcare & 7 others	65/100
5th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Deerfield & 9 others	64/100
6th	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Wellington, Celgene & 10 others	63/100
7th	AIRNA 2021, Cambridge (United States), Series B	Developer of gene therapies for rare and common diseases	$245M	Forbion, Venrock & 9 others	63/100
8th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Foresite Capital & 11 others	62/100
9th	American Gene 2008, Rockville (United States), Series B	Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases	$53.1M	Ride wave ventures, Gaingels & 3 others	60/100
10th	Cycle Pharma 2012, Cambridge (United Kingdom), Funding Raised	Small molecule drug reformulation and repurposing for orphan indications	-	robinson-family.ca, Michael A Tory Trust ... & 31 others	59/100
107th	AVROBIO 2019, Cambridge (United States), Deadpooled	Provider of lentiviral gene therapy for the treatment of Fabry diseases	-	-	25/100